Robert Coffin
Person
Melanoma patients
HSV-based vectors
shuttle plasmids
Technique for the large-scale generation of DC in serum-free medium under GMP conditions
Technology for delivery of antigens to DC
Metastatic Cutaneous Melanoma Patients
DC from melanoma patients
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
ImmunoVex HSV2
Measuring of human immune responses to melanoma antigens
Allogeneic dendritic cell fusion vaccines
Glioblastoma patients
50 patient phase II clinical trial for melanoma
Prevention of infectious disease is ImmunoVex HSV2 a vaccine for genital herpes
HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes
In vitro antigen presentation assay
In vitro priming of tumor-antigen specific T-cells
In vitro recognition of fusion vaccine by T-cells
Detection of tumour-specific CD8+ T-cells in the blood of glioblastoma patients